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Abstract
This study was conducted to determine whether single nucleotide polymorphisms (SNPs) in nine 
genes (human leukocyte antigen (HLA), T cell receptor beta (TCA receptor β), tumor necrosis 
factor α (TNF α), tumor necrosis factor β (TNF β), apolipoprotein E (APOE), interleukin 7 
receptor alpha chain (IL7RA) interleukin 2 receptor alpha chain (IL2RA) myelin basic protein 
(MBP) and vitamin D receptor (VDR)) associated with multiple sclerosis (MS) could be replicated 
in a population-based sample, and to determine if these associations are modified by presence of 
HLA DRB1*1501. DNA was available from 722 individuals (223 with MS and 499 controls) who 
participated in a population-based case-control study. Cases and controls were matched on 
ancestry, age, gender and geographic area. HLA DRB1*1501 risk allele (T) was confirmed in this 
population using a genotypic test, controlling for multiple comparisons. Examining the effect of 
each SNP in the presence or absence of the HLA DRB1*1501 risk allele identified significant 
associations with TNF α -1031 (rs1799964) among those without the HLA risk allele. No 
additional interactions were significant in a cases-only analysis. Our results indicate that an 
interaction between SNPs in TNF α and HLA DRB1*1501 may influence the risk of developing 
MS.
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Family studies have demonstrated that genetic and non-genetic factors are involved in the 
etiology of multiple sclerosis (MS) [1-2]. Heritability estimates of up to 76% from twin 
studies provide the most convincing evidence for a genetic component [3]. Studies of 
multiplex families, half-siblings and adoptees also provide evidence for a genetic 
contribution to disease susceptibility [1]. The sole consistent genetic association identified 
with MS is the human leukocyte antigen (HLA) [4]. Other immune-mediated genes such as 
immunoglobulin heavy chain (IgH), T-cell receptor (TCR), tumor necrosis factor (TNF) and 
myelin basic protein (MBP) have also been associated with MS [5-6]. Classic linkage and 
affected sib-pair linkage studies have been conducted examining these genes as potential 
risk factors but the results have been conflicting [1,3].
Genome-wide association studies have also been conducted to localize genomic regions that 
may harbor novel MS susceptibility genes in unrelated individuals [7-10] and parent-
affected child trios [11]. These studies used large sets of polymorphic markers that spanned 
the genome and identified additional risk loci, supporting the hypothesis that MS is 
polygenic and genetically heterogeneous. Overall, HLA DRB1*1501, interleukin 2 receptor 
alpha chain (IL2RA) and interleukin-7 receptor alpha chain (IL7RA) genes have been the 
most consistently replicated and have shown the strongest associations [6,7].
The aims of this study were to determine whether single nucleotide polymorphisms (SNPs) 
in nine genes previously reported to be associated with MS could be replicated in a 
population based sample and to determine if these associations are modified by having the 
HLA DRB1*1501 risk allele.
2. Materials and Methods
2.1. Ethics Statement
Written informed consent was obtained from all participants. This study was approved by 
the Institutional Review Boards of the Centers for Disease Control and Prevention, Duke 
University Medical Center, Michigan Public Health Institute, the Texas Department of State 
Health Services, and the Cleveland Clinic.
2.2. Study Population
Study participants were individuals with MS and controls who participated in a population-
based case-control study conducted from November 2004 to September 2009 [12]. Cases 
were identified from a prevalence study conducted in four geographic areas (metro Atlanta, 
Georgia; Lorain County, Ohio; the cities of Independence and Sugar Creek, Missouri; or the 
19-county area surrounding Lubbock, Texas) and were classified as having definite MS 
according to both the Poser [13] and McDonald [14] criteria by a study neurologist [12]. 
Controls were recruited by random digit dialing and are matched to cases on sex, age, race 
and geographic area.
The case-control study enrolled 276 cases and 590 matched controls (n=866) [12]. Because 
allele frequencies and disease risk differ across racial and ethnic groups [15] we restricted 
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our analysis to Whites to ensure a homogeneous population. Data from 60 non-White 
individuals were excluded from the analysis as were data from 84 white participants who did 
not provide a blood sample (24 cases and 60 controls). This resulted in a total of 722 
individuals (223 cases and 499 controls) in 212 strata for the analyses presented here. The 
majority of the strata were either 1:1 or 1:2 matched (62.3%).
2.3. Specimen Collection and DNA Extraction
Each participant was asked to provide a blood sample (3 EDTA Starstedt tubes of whole 
blood) for genetic analysis. All samples were labeled by a unique identifier so technicians 
were blinded to case/control status. The Center for Human Genetics at Duke University 
Medical Center conducted the genotyping. DNA was extracted using the PUREGENE 
system (QIAGEN, Germantown, MD).
2.4. Candidate Gene and SNP Selection
Seven candidate genes were selected for confirmatory analysis based on published evidence 
that they play a role in the development of MS: human leukocyte antigen (HLA), T cell 
receptor beta (TCA receptor β), tumor necrosis factor α (TNF α), tumor necrosis factor β 
(TNF β), apolipoprotein E (APOE), interleukin 7 receptor alpha chain (IL7RA) and 
interleukin 2 receptor alpha chain (IL2RA). We selected 13 SNPs (HLA, n=1; TCA receptor 
β, n=2; TNF α/β, n=6; APOE, n=2; IL7RA, n=1; and IL7RA, n=1) that had been previously 
reported as associated with MS [4-7, 16].
Two additional candidate genes were selected for exploratory analysis based on biological 
plausibility: myelin basic protein (MBP) and vitamin D receptor (VDR) [17-20]. For VDR 
and MBP genes, haplotype tagging SNPs were identified using LDSelect v1.0 (30) based on 
data from the CEU population in the HapMap project (www.hapmap.org). To minimize 
redundancy among SNPs in high linkage disequilibrium, single SNPs were selected to 
represent each haplotype block, as defined by r2 > 0.64. SNPs were prioritized based on the 
potential for biological effect (coding SNPs, 5′/3′ untranslated and regulatory regions), 
physical position, and allele frequency. Forty-five exploratory SNPs were selected in the 
VDR and MBP genes (n=22 and n=23 respectively).
2.5. Genotyping
Genotyping was conducted using the Applied Biosystems Taqman platform at the Center for 
Human Genetics, Duke University Medical Center. Quality control measures applied for all 
genotyping assays included the genotyping of a series of blinded duplicate samples and 
Centre d'Etude du Polymorphism Humain (CEPH) controls. To pass quality control, all 
duplicate samples in an assay had to match 100%.
2.6. Statistical Analysis
Differences in demographic characteristics between cases and controls were analyzed using 
a chi-square test. Tests for deviations from Hardy-Weinberg equilibrium (HWE) were 
conducted in controls using PLINK [21]. SNPs that failed HWE (p ≤ 0.005) were excluded 
from further analyses. We controlled for population stratification using questionnaire data 
regarding ancestry information. Participants were asked to list up to three countries where 
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their maternal ancestors came from and up to three countries where their paternal ancestors 
came from. Responses were grouped into geographic areas (Western Europe, Eastern 
Europe, Mediterranean, Scandinavia, US/Canada/Don't know). Each participant's proportion 
of ancestry from each geographic region was entered as a covariate in the analysis. 
Education was dichotomized as high school education or less versus post high school 
education.
Matched strata contained between 1– 4 cases and 1 – 12 controls. Genotype was coded as a 
quantitative variable that counts the number of minor alleles for each individual. HLA 
DRB1*1501 risk was defined as having at least one copy of the risk allele (T). Because cases 
and controls were matched, data were analyzed using conditional logistic regression. For 
genetic main effects, we fit models that included SNP genotype while adjusting for 
education and ancestry. For analyses of interaction, we fit models that included SNP 
genotype, HLA DRB1*1501 risk, and a multiplicative SNP × HLA DRB1*1501 risk 
interaction term, while again adjusting for education and ancestry. An unmatched cases-only 
analysis was conducted using unconditional logistic regression with HLA DRB1*1501 risk 
as the outcome and each SNP genotype as a predictor; also included in each model were 
education and ancestry. Assuming independence (i.e., no linkage disequilibrium) between a 
SNP and HLA DRB1*1501, an association found among cases would be evidence for gene x 
gene interaction. SNPs in TNF α and TNF β were not included in this analysis because they 
are in linkage disequilibrium (LD) with HLA DRB1*1501. Since this analysis makes an 
extra assumption about linkage disequilibrium, it may be more powerful than the matched 
analysis [22].
Analyses involving the 13 SNPs previously found associated with MS were considered as 
confirmatory, and were not adjusted for multiple comparisons. Analyses involving the 22 
VDR and 23 MBP SNPs are considered exploratory; for these SNPs, adjustments for 
multiple comparisons were made using the Bonferonni correction (by adjusting the p value 
cutoff to correspond to a size of 0.05/45). SAS, version 9.2 (SAS Institute, Cary, NC, USA) 
was used for data management and statistical analysis.
3. Results
Most study participants were female, ≥50 years old and had attended or graduated from 
college (Table 1). The female-to-male ratio was 4.09:1. The majority (80%) of study 
participants had complete genotype information, while approximately 6% were missing 
genotype information for two or more SNPs. Nearly three-quarters of the cases reported 
having relapsing remitting MS (Table 2). Most reported the onset of symptoms in their early 
thirties and were diagnosed in their late thirties, and had had MS for over 10 years.
The chromosomal location, gene name, SNP reference sequence (rs) number, minor allele 
and minor allele frequencies for each SNP included in this analysis are shown in Table 
3.The minor allele frequencies in this population varied dramatically across SNPs and 
ranged from 0.02 to 0.49. None of the SNPs selected failed HWE. Two confirmatory SNPs 
were significantly associated with MS at the 0.05 level: TNF β (rs909253) and HLA 
DRB1*1501 (rs3135388). Five exploratory SNPs in the MBP gene (rs9676113, rs595997, 
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rs2974260, rs12967023, and rs8096433) were significant at the 0.05 level, but did not 
remain significant after correction for multiple comparisons.
We also examined the effect of each SNP in the presence or absence of the HLA 
DRB1*1501 risk allele (T) (Table 4). One of the confirmatory SNPs was associated with MS 
among participants with no HLA DRB1*1501 risk allele (TNFα rs1799964, odds ratio per 
copy of the minor allele (OR) 1.77, 95% confidence interval (CI) 1.17, 2.69). Two 
exploratory SNPs were associated with MS among participants with no HLA DRB1*1501 
risk allele: VDR rs2189480 (OR 1.54, 95% CI 1.07, 2.23) and MBP rs9676113 (OR 0.48, 
95% CI 0.30, 0.76). No SNPs were associated with MS among participants with the HLA 
DRB1*1501 risk allele. In the cases-only analysis for interaction between HLA DRB1*1501 
risk and the other loci (Table 4), two SNPs were significant at p≤ 0.05 level (VDR 
rs2189480 and MBP rs3794848). However, none of the exploratory interactions were 
statistically significant after adjustment for multiple comparisons. Finally, when we repeated 
our analyses without adjusting for ancestry, we found similar p-values and effect estimates 
(data not shown).
4. Discussion
In this population based case-control study, we examined the association of 58 SNPs in nine 
previously reported candidate genes and having MS. We confirmed an association with two 
SNPs previously identified in the literature (TNF β and HLA DRB1*1501) and found an 
association with a TNF α SNP that was limited to individuals who lack the HLA 
DRB1*1501 risk allele. Because we only examined statistical interaction, it is impossible to 
determine if this is a true biological interaction, or simply that the smaller TNF α effect is 
easier to detect among persons without the HLA DRB1*1501 risk allele. If this is the case, it 
may be reasonable to accept the nominal p-value for this “interaction” without adjustment 
for multiple comparisons. Further, because there is linkage disequilibrium between TNF α 
and the HLA region, we cannot rule out the possibility that the TNF α effect we see is 
actually the result of different risk allele in the HLA region.
Associations between polymorphisms in the TNF-α -1031 T/C (rs1799964) polymorphism 
and immune-mediated diseases such as Crohn's disease, rheumatoid arthritis and Graves' 
disease have been reported [23-25]. Studies examining the association between TNF α and 
MS have been conflicting, and have usually focused on the TNF α -308 polymorphism 
(rs1800629) [26-34]. A study in men of Russian and Tatar ethnic origin found that 
susceptibility to MS was influenced by the HLA DRB1*1501 SNP rs909253 and TNF α 
SNP rs1800629 [35]. Another case-control study conducted with an Iranian population 
reported an interaction between HLA-DRB1*1501 and TNF α SNP rs1800629, with a 7-
fold increased odds of MS among individuals with at least one copy of the risk allele [26]. 
We also found an interaction between HLA DRB1*1501 and TNF-α but with at a different 
locus (rs1799964). However, rs1799964 is in strong LD with rs1800629 in our study 
population (D′ = 1), and the haplotype having the minor allele at both loci is completely 
absent in our study population. Strong LD in the region suggests that different SNPs in TNF 
α may be associated with MS in different populations. Taken together, these studies strongly 
suggest a causal SNP resides somewhere in this region.
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Tumor necrosis factor (TNF) is an important pro-inflammatory cytokine which plays a role 
in the regulation of cell differentiation, proliferation and death, as well as in inflammation, 
innate and adaptive immune responses [23]. The exact role of the TNF superfamily is 
unclear although they are the principal mediators in immune defense, inflammation and the 
development and maintenance of the immune system [36]. TNF-α is a pleiotropic cytokine 
with wide-ranging actions on the immune system and is an important mediator in immune-
mediated inflammatory disease states, including multiple sclerosis [36]. The presence of 
DNA sequence variations in the regulatory region might interfere with transcription of TNF 
gene, influencing the circulating level of TNF and consequently susceptibility to 
autoimmune and other neurodegenerative diseases [23]. In addition, clinical observations 
have implicated dysregulation of the TNF-α pathway in susceptibility to MS. In a clinical 
trial, patients who received lenercept, a p55 tumor necrosis factor receptor fusion protein, 
had increased relapse activity compared to patients who received a placebo [37]. A clinical 
trial of an anti-TNF antibody was associated with increased disease activity, and 
demyelinating disease has emerged in persons treated with monoclonal antibodies to TNF-α 
for indications such as inflammatory bowel disease and rheumatoid arthritis [38-39]. It is 
unclear whether the interaction between HLA and TNF α is biological or merely that the 
weaker effect of TNF α is more easily detected when the HLA risk allele is absent. 
However, HLA haplotypes are known to affect the synthesis of TNF-α, with some 
haplotypes increasing TNF α synthesis and others decreasing TNF α synthesis [40-41].
We found five SNPs in the myelin basic protein gene that were associated with MS. One of 
these (rs9676113) had a p-value of 0.0073 when testing its main effect and a p-value of 
0.0022 among persons with no HLA risk. While these results were not significant after 
adjusting for multiple comparisons, the small p-values we observed suggest that association 
between SNPs in MBP (especially rs9676113) and MS warrants further research.
Since MS predominantly affects individuals who are white and female, most research 
conducted in this field has focused specifically on this population. A limitation of our study 
was that we identified very few individuals who were non-white and thus could not evaluate 
whether the identified association was also present across populations. It is unknown if the 
genetic contributions to this disease identified in this study will be confirmed in other racial/
ethnic groups. Another limitation in this study was that we looked at common variations in 
the selected candidate genes. Our results do not rule out the possibility that rare variants may 
also contribute in these and other genes.
5. Conclusions
Research has shown that a single locus model for MS is unlikely. Our work adds to the 
emerging literature regarding gene-gene interactions, particularly those related to immune 
regulation. Future efforts should focus on evaluating this finding in both population-based 
and family studies, and on evaluating this finding in non-White populations. Consistent 
replication of these results in different populations would support causality. Evaluation of 
the potential effects of an interaction between TNF- α and HLA, and the possible role of 
MBP, may offer insights into the mechanisms of disease as well.
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Table 1






State of Residence (n, %)
1.13 (0.77)
Georgia 72 (32.3) 151 (30.2)
Missouri 18 (8.1) 51 (10.2)
Ohio 75 (33.6) 161 (32.3)
Texas 58 (26.0) 136 (27.3)
Sex (n, %)
0.21 (0.64)Female 179 (80.3) 393 (78.8)
Male 44 (19.7) 106 (21.2)
Age (years) (n, %)a
12.96 (0.01)
< 39 2 (9.9) 34 (6.8)
40 – 49 57 (25.6) 106 (21.2)
50 – 59 99 (44.4) 196 (38.9)
60 – 69 34 (15.2) 127 (25.5)
70+ 11 (4.9) 38 (7.6)
Educational Status Attained (n, %)
2.6 (0.47)
< High School 8 (3.6) 19 (3.8)
High School graduate 48 (21.5) 84 (16.8)
Some College/Technical School 69 (30.9) 154 (30.9)
College Graduate 98 (44.0) 242 (48.5)
Number of missing genotypes
9.14 (0.10)
0 168 (75.3) 409 (82.0)
1 38 (17.0) 65 (13.0)
2 4 (1.8) 13 (2.6)
3 3 (1.4) 4 (0.8)
4 4 (1.8) 2 (0.4)
>5 6 (2.7) 6 (1.2)
a
At time of interview
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Table 2
Characteristics of the individuals with MS
Type of MS
Relapsing remitting 160 (71.8)
Primary progressive 21 (9.4)
Secondary progressive 5 (2.2)
Don't know 37 (16.6)
Age at onset of symptoms
Mean 32.7
Standard deviation 9.4
Duration of MS since symptom onset a
< 5 years 8 (3.6)
5-10 years 38 (17.1)




Duration of MS since diagnosisb
< 5 years 15 (6.8)
5-10 years 69 (31.1)
> 10 years 138 (62.1)
a
One individual did not know their date of symptom onset and was excluded.
b
Four individuals did not know their date of diagnosis and were excluded
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